Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.
about
The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-AnalysisOver- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropeniaPatterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOPTherapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.Febrile neutropenia in chemotherapy treated small-cell lung cancer patientsAssociation of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer PatientsIncidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy.Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.Developing a tool for nurses to assess risk of infection in pediatric oncology patients in China: a modified Delphi study.Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study.Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Retrospective Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.Non-chemotherapy drug-induced neutropenia - an update.Validation of MASCC Score for Risk Stratification in Patients of Hematological Disorders with Febrile Neutropenia.Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma.Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle.Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).Evaluation of pegfilgrastim use at an academic medical center.Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy.
P2860
Q26786142-AE9A1035-C155-4357-A512-5C36662D8D8BQ33599892-E41C1ED4-651A-4F6F-940E-937FDDB1CE20Q34403621-C532370D-FD5F-47F4-AA59-055CF1C3F872Q34528537-98004158-9306-416B-B076-2CFA45B82308Q34670717-D1DFA8C6-8A5D-4800-8C1C-4C3BE77C7E2DQ35165571-FA20D5EF-3AF6-4B59-8E20-04978D67944AQ35297079-A52D306A-4B19-4D4A-8F4D-B89AB96BB55FQ36236476-35A1F4FF-B769-4D89-828E-95FF7371E9DDQ36769011-87C05BF9-4254-4ACE-A7CC-4ADDDBE1C448Q36885665-59133DAB-EDD9-4E66-A41D-351A11C2E0B3Q37300122-9A8DE216-8D5D-4614-88A2-EF69258F8CF2Q37387974-7CE24316-51A4-472E-BBAF-EDFF3D203DF9Q37579007-60915A98-AE2F-4618-A280-E535069219CFQ38682028-76BCD579-FCC4-4337-82BA-73EEDD86CCF4Q38749061-028BF6B4-2642-4CB3-869F-1A393A8D0B45Q38823135-27B3918A-BF29-408D-936E-9F43E25D30A9Q39361614-AA62A709-8780-4ECD-835B-0FE85EA43837Q40055208-B4D6581E-8EE6-425C-8C7D-081633D4E82DQ40063054-55ACFC1E-54B6-4DFB-8976-BD7BA9332B2FQ40086539-39CC5907-3572-48C5-9A66-DF629C994B43Q40141879-EEC79EDA-66E0-4E11-99FD-59635028AC0CQ40163155-F3679029-8B9D-46E0-95FF-4FD968A8CC09Q40410427-B96E29AA-9C3D-42CB-B649-9C9DFD4863B1Q41349270-F686F2A0-1C15-438F-967D-C1C7F2729266Q45746480-2564977C-E5C3-4BCC-928B-B4AB80FF7AD5Q47213188-148E5EA6-3301-4F9D-A984-C98CF215547FQ48808489-9F7187AF-6B60-406E-96C1-FFAEC8B4B505Q50509522-5A020B2F-4B44-4A7C-8753-8A58BE910FC9Q52776197-502F6631-CA91-4F7E-B85E-74F4DB3E7584
P2860
Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Risk factors for febrile neutr ...... otherapy: A systematic review.
@ast
Risk factors for febrile neutr ...... otherapy: A systematic review.
@en
Risk factors for febrile neutr ...... otherapy: A systematic review.
@nl
type
label
Risk factors for febrile neutr ...... otherapy: A systematic review.
@ast
Risk factors for febrile neutr ...... otherapy: A systematic review.
@en
Risk factors for febrile neutr ...... otherapy: A systematic review.
@nl
prefLabel
Risk factors for febrile neutr ...... otherapy: A systematic review.
@ast
Risk factors for febrile neutr ...... otherapy: A systematic review.
@en
Risk factors for febrile neutr ...... otherapy: A systematic review.
@nl
P2093
P1476
Risk factors for febrile neutr ...... otherapy: A systematic review.
@en
P2093
Esteban Abella
Gary H Lyman
Ruth Pettengell
P304
P356
10.1016/J.CRITREVONC.2013.12.006
P577
2013-12-12T00:00:00Z